December 3, 2019
In the second settlement to come out of a federal investigation into the generic pharmaceutical industry, Rising Pharmaceuticals Inc.
has agreed to pay over $4 million
to settle civil and criminal charges stemming from violations of the False Claims Act and Anti-Kickback Statute. In the criminal case, Rising allegedly teamed up with a competing generic drug manufacturer to fix prices and divide up the market for a hypertension drug, Benazepril HCTZ, while in the civil case, the company allegedly paid and received illegal remuneration through similar arrangements with another generic drug manufacturer. Under the newly signed deferred prosecution agreement, Rising has agreed to cooperate fully with the ongoing investigation. DOJ
; USAO EDPA